ReviewJournal of clinical medicine2021
Chordoma-Current Understanding and Modern Treatment Paradigms.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.Frontiers in oncology · 2022Pooled it
- Incidence patterns and trends of chordoma in the United States: a population-based analysis of over 6,000 cases.Journal of bone oncology · 2026Article
- Techniques to Reduce Iatrogenic Nasal Seeding in Endoscopic Endonasal Surgery for Skull Base Chordoma.Journal of neurological surgery. Part B, Skull base · 2026Article
- Voiding dysfunction in pelvic organ prolapse mimicking obstruction: an unusual presentation of sacral chordoma - A case report.BMC urology · 2026Article
- CT perfusion-focused preoperative assessment of the blood-supplying state among imaging modalities in skull base chordoma: a retrospective single-center cohort.Journal of neuro-oncology · 2026Article
- Correlation Between Molecular Genetic Analysis and Nuclear Pleomorphism in Long-Term Recurrent and Metastatic Chordoma.Cancers · 2026Article
- Hemicorporectomy: a case report on a last-resort surgical procedure.World journal of surgical oncology · 2026Article
- Paraspinal Skip Lesion Encountered During the Resection of a Sacral Chordoma: A Case Report.Cureus · 2026Article
- Extra-axial chordoma of the distal femur: a clinical and radiological challenge-case report and literature review.Skeletal radiology · 2026Review
- CircRNAs in Immuno-Metabolic Reprogramming of Chordoma Cancer: Molecular Crosstalk and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Distinguishing Benign Notochordal Cell Tumors From Chordoma in a Patient With Multicentric Spinal Lesions.Case reports in radiology · 2026Article
- AI-assisted identification of innovative phytochemicals from Aizoon canariense aimed at brachyury protein in chordoma: a computational strategy.Scientific reports · 2025Article
- Metastatic sacral chordoma presenting as a cecal polyp: a case report.Journal of surgical case reports · 2025Article
- Unveiling Primary Bone Tumors of the Spine: A Review of Essential Imaging Clues.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- A clinical analysis of 19 cases of chordomas with poor differentiation treated using diverse therapeutic modalities.Discover oncology · 2025Article
- Real-time prognosis prediction with conditional survival analysis for skull base chordoma based on SEER.Translational cancer research · 2025Article
- Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer.Cancer biology & medicine · 2025Review
- Posterior Mediastinal Chordoma Resected With Anterior Thoracic Vertebral Body Through Prone Bilateral Thoracic Approaches.Annals of thoracic surgery short reports · 2025Article
- Recurrence Patterns After Resection of Sacral Chordoma: Toward an Optimized Postoperative Target Volume Definition.Cancers · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoma is a low-grade notochordal tumor of the skull base, mobile spine and sacrum which behaves malignantly and confers a poor prognosis despite indolent growth patterns. These tumors often present late in the disease course, tend to encapsulate adjacent neurovascular anatomy, seed resection cavities, recur locally and respond poorly to radiotherapy and conventional chemotherapy, all of which make chordomas challenging to treat. Extent of surgical resection and adequacy of surgical margins are the most important prognostic factors and thus patients with chordoma should be cared for by a highly experienced, multi-disciplinary surgical team in a quaternary center. Ongoing research into the molecular pathophysiology of chordoma has led to the discovery of several pathways that may serve as potential targets for molecular therapy, including a multitude of receptor tyrosine kinases (e.g., platelet-derived growth factor receptor [PDGFR], epidermal growth factor receptor [EGFR]), downstream cascades (e.g., phosphoinositide 3-kinase [PI3K]/protein kinase B [Akt]/mechanistic target of rapamycin [mTOR]), brachyury-a transcription factor expressed ubiquitously in chordoma but not in other tissues-and the fibroblast growth factor [FGF]/mitogen-activated protein kinase kinase [MEK]/extracellular signal-regulated kinase [ERK] pathway. In this review article, the pathophysiology, diagnosis and modern treatment paradigms of chordoma will be discussed with an emphasis on the ongoing research and advances in the field that may lead to improved outcomes for patients with this challenging disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.